LFB building first U.S. manufacturing facility

Pregnant belly

LFB USA, the Framingham, MA-based unit of France’s LFB Group, is building its first manufacturing facility in the U.S.

The biotech is investing $37 million to build a 65,000-square-foot manufacturing and laboratory facility in Marlborough, MA, according to the Milford Daily News. The company, which is getting incentives from the city, plans to add 50 jobs when the project is complete next year.

The plant will be used for early-stage processing of ATryn, a drug given to patients before surgery or childbirth who have a hereditary disease that can lead to blood clots. The drug will also be manufactured for rEVO Biologics, another unit of LFB, which is doing clinical trials on ATryn for treating the pregnancy complication preeclampsia.


[Infographic] Machine Learning, Statistics and Optimizing Outcomes

In our infographic, we outline the potential of fusing machine learning and statistics algorithms together to more efficiently analyze clinical trial data output and ultimately revolutionize clinical research.

“This is our signature capital investment,” William Gavin, LFB USA president said during a groundbreaking event, the newspaper reported.  “We really need to scale this up for the market demand.”

- read the Daily News story 

Related Article: 
REVO looks to expand use of Atryn with preeclampsia PhIII

Suggested Articles

Novartis' AveXis will use Catalent for some manufacturing of its newly approved gene therapy Zolgensma and more manufacturing news of note.

Pharmacy chain Rite Aid has partnered with Google to have their drug recycling stations easily searchable on Google Maps. 

Precision BioSciences says it will have a manufacturing facility for its off-the-shelf CAR-T therapies up and running in the fourth quarter.